Sapu Nano Unveils Broad-Applicability Deciparticle™ Nanomedicine Platform Capable of Formulating Multiple Hydrophobic Peptide, Macrolide, and Polyketide Drugs

Sapu Nano, a clinical-stage nanomedicine company, today announced new data demonstrating that its proprietary Deciparticle™ platform enables broad and consistent formulation of structurally diverse ...
manilatimes

Aanastra Inc Announces Presentations of Preclinical Data at Upcoming Conferences in Support of its Lead Programs for Anti-CD19 In Vivo CAR-T (AAN-14x) and In vivo Rescue of P53 ...

Greater than 90% depletion of B cells within 12 hours of a single dose of AAN-14x Multiple redosing of AAN-14x at desired intervals with no evidence of hepatic or other toxicity Remarkable tumor ...
News Medical

Study identifies mechanism behind SARS-CoV-2 fusion of host cells

The spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is mediated by the fusion of the spike protein to nearby healthy cells. New research by German researchers sheds light on how ...

Oncotelic and Sapu Nano Unveils Broad-Applicability Deciparticle™ Nanomedicine Platform Capable of Formulating Multiple Hydrophobic Peptide, Macrolide, and Polyketide Drugs

Oncotelic Therapeutics, Inc. (OTCQB: OTLC) 45% owned Joint Venture, Sapu Nano, a clinical-stage nanomedicine company, today announced new data demonstrating that its proprietary Deciparticle™ platform ...